Fecal calprotectin variability in Crohn's disease

Inflammatory Bowel Diseases

Volumn 16, Issue 7, 2010, Pages 1091-1092

  Moum, Bjørn ^a   Jahnsen, Jørgen ^a   Bernklev, Tomm ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FECES; FECES ANALYSIS; FECES LEVEL; HUMAN; LETTER; PRIORITY JOURNAL; ULCERATIVE COLITIS;

CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 77953693767     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21136     Document Type: Letter

References (4)

1. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
2. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009 [Epub ahead of print] PMID: 19363798.
3. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.
4. Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14:1392-1398.